Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Aberrant CBFA2T3B gene promoter methylation in breast tumors.

Bais AJ, Gardner AE, McKenzie OL, Callen DF, Sutherland GR, Kremmidiotis G.

Mol Cancer. 2004 Aug 10;3:22.

2.

Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.

Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S.

Clin Cancer Res. 2005 Feb 15;11(4):1380-5.

3.

Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer.

Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, Suzuki M, Chen H, Hsieh JT, Gazdar AF, Shimizu N.

Clin Cancer Res. 2004 Mar 15;10(6):2082-9.

4.

Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.

Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knüchel R, Dahl E.

Breast Cancer Res. 2008;10(5):R82. doi: 10.1186/bcr2151. Epub 2008 Sep 30.

5.

Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes.

Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas-Jones A, Mokbel K, Mansel RE.

Eur J Cancer. 2005 Jul;41(11):1628-36.

PMID:
15951164
6.

RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.

Peters I, Rehmet K, Wilke N, Kuczyk MA, Hennenlotter J, Eilers T, Machtens S, Jonas U, Serth J.

Mol Cancer. 2007 Jul 16;6:49.

7.

Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.

Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knüchel R, Dahl E.

Mol Cancer. 2008 Nov 6;7:83. doi: 10.1186/1476-4598-7-83.

8.

Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.

Chen ST, Lin SY, Yeh KT, Kuo SJ, Chan WL, Chu YP, Chang JG.

Int J Mol Med. 2004 Oct;14(4):577-82.

PMID:
15375584
9.

Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.

Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P.

Cancer Res. 2008 Feb 15;68(4):998-1002. doi: 10.1158/0008-5472.CAN-07-2418.

10.

Promoter methylation of the PTEN gene is a common molecular change in breast cancer.

García JM, Silva J, Peña C, Garcia V, Rodríguez R, Cruz MA, Cantos B, Provencio M, España P, Bonilla F.

Genes Chromosomes Cancer. 2004 Oct;41(2):117-24.

PMID:
15287024
11.

Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.

Kobatake T, Yano M, Toyooka S, Tsukuda K, Dote H, Kikuchi T, Toyota M, Ouchida M, Aoe M, Date H, Pass HI, Doihara H, Shimizu N.

Oncol Rep. 2004 Nov;12(5):1087-92.

PMID:
15492797
12.

Promoter methylation reduces C/EBPdelta (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors.

Tang D, Sivko GS, DeWille JW.

Breast Cancer Res Treat. 2006 Jan;95(2):161-70. Epub 2005 Dec 2.

PMID:
16322893
13.

Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.

Imura M, Yamashita S, Cai LY, Furuta J, Wakabayashi M, Yasugi T, Ushijima T.

Cancer Lett. 2006 Sep 28;241(2):213-20. Epub 2005 Nov 21.

PMID:
16303245
14.

Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.

Jiang Y, Tong D, Lou G, Zhang Y, Geng J.

Pathobiology. 2008;75(4):244-51. doi: 10.1159/000132385. Epub 2008 Jun 26.

PMID:
18580070
15.

CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3.

Kochetkova M, McKenzie OL, Bais AJ, Martin JM, Secker GA, Seshadri R, Powell JA, Hinze SJ, Gardner AE, Spendlove HE, O'Callaghan NJ, Cleton-Jansen AM, Cornelisse C, Whitmore SA, Crawford J, Kremmidiotis G, Sutherland GR, Callen DF.

Cancer Res. 2002 Aug 15;62(16):4599-604.

16.

Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression.

Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, Pandya P, Ralhan R.

Tumour Biol. 2011 Feb;32(1):23-32. doi: 10.1007/s13277-010-0087-8. Epub 2010 Aug 10.

PMID:
20697987
17.

HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma.

Yamashita K, Kim MS, Park HL, Tokumaru Y, Osada M, Inoue H, Mori M, Sidransky D.

Mol Cancer Res. 2008 Jan;6(1):31-41. doi: 10.1158/1541-7786.MCR-07-0213.

18.

Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors.

Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, Rabitti C, Rinaldi M, Nicol T, Tommasi S, Paradiso A, Schittulli F, Altomare V, Fazio VM.

Clin Cancer Res. 2004 Aug 15;10(16):5349-54.

19.

Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.

Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93.

20.

Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.

Kong WJ, Zhang S, Guo C, Zhang S, Wang Y, Zhang D.

Laryngoscope. 2005 Aug;115(8):1395-401.

PMID:
16094112
Items per page

Supplemental Content

Write to the Help Desk